The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

Start Date01 Jul 2024

Sponsor / Collaborator-

IRCT20151221025641N8 / SuspendedPhase 3IIT

Comparison of the efficacy of oral and intranasal midazolam premedication on sedation before undergoing MRI in children

Start Date04 Jun 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

NCT06407518 / Not yet recruitingNot ApplicableIIT

Effects of Preoperative Oral Mmidazolam on Postoperative Pain in Sleep Disturbance or Anxiety Patients Undergoing Laparoscopic Colorectal Cancer Resection- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study

Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher risk of chronic pain. The enhancement of sleep quality is intricately linked to reducing stress. Preoperative drugs that combine hypnosis and anti-anxiety have not been studied in colorectal cancer patients. Midazolam oral solution is safe and effective for short-term hypnotic and anti-anxiety effects in clinical preoperative settings. In the current randomized controlled clinical trial, 280 patients experiencing sleep disturbance or anxiety prior to colorectal cancer surgery will receive midazolam solution to assess its potential efficacy in reducing postoperative pain, expediting recovery, and decreasing the likelihood of chronic pain. Additionally, the study aims to explore the potential connections between midazolam administration and reductions in stress and inflammation.

Start Date01 Jun 2024

Sponsor / Collaborator

The Sixth Affiliated Hospital of Sun Yat-Sen University

100 Clinical Results associated with Midazolam

100 Translational Medicine associated with Midazolam

100 Patents (Medical) associated with Midazolam

14,844

Literatures (Medical) associated with Midazolam

01 Jun 2024·Journal of critical care

Multicentre implementation of a quality improvement initiative to reduce delirium in adult intensive care units: An interrupted time series analysis

Article

Author: Colaco, Heather ; Stelfox, Henry T ; Dyjur, Donalda ; Wickson, Patty ; Sinnadurai, Selvi ; Fiest, Kirsten M ; Redlich, Melissa ; Owen, Victoria S ; Faris, Peter D ; Harris, Jo ; Doig, Christopher J ; Zygun, David A ; Morrissey, Jeanna ; O'Neill, Barbara ; Niven, Daniel J ; Zuege, Danny J

PURPOSE:

The ABCDEF bundle may improve delirium outcomes among intensive care unit (ICU) patients, however population-based studies are lacking. In this study we evaluated effects of a quality improvement initiative based on the ABCDEF bundle in adult ICUs in Alberta, Canada.

MATERIAL AND METHODS:

We conducted a pre-post, registry-based clinical trial, analysed using interrupted time series methodology. Outcomes were examined via segmented linear regression using mixed effects models. The main data source was a population-based electronic health record.

RESULTS:

44,405 consecutive admissions (38,400 unique patients) admitted to 15 general medical/surgical and/or neurologic adult ICUs between 2014 and 2019 were included. The proportion of delirium days per ICU increased from 30.24% to 35.31% during the pre-intervention period. After intervention implementation it decreased significantly (bimonthly decrease of 0.34%, 95%CI 0.18-0.50%, p < 0.01) from 33.48% (95%CI 29.64-37.31%) in 2017 to 28.74% (95%CI 25.22-32.26%) in 2019. The proportion of sedation days using midazolam demonstrated an immediate decrease of 7.58% (95%CI 4.00-11.16%). There were no significant changes in duration of invasive ventilation, proportion of partial coma days, ICU mortality, or potential adverse events.

CONCLUSIONS:

An ABCDEF delirium initiative was implemented on a population-basis within adult ICUs and was successful at reducing the prevalence of delirium.

01 Mar 2024·Anesthesia and analgesia

Bispectral Index Changes Following Boluses of Commonly Used Intravenous Medications During Volatile Anesthesia Identified From Retrospective Data

Article

Author: Schnetz, Michael P ; Mahajan, Aman ; Vogt, Keith M ; Reon, Brian J ; Kaynar, Murat ; Ibinson, James W

BACKGROUND::

Although patients are commonly monitored for depth of anesthesia, it is unclear to what extent administration of intravenous anesthetic medications may affect calculated bispectral (BIS) index values under general anesthesia.

METHODS::

In a retrospective analysis of electronic anesthesia records from an academic medical center, we examined BIS index changes associated with 14 different intravenous medications, as administered in routine practice, during volatile-based anesthesia using a novel screening approach. Discrete-time windows were identified in which only a single drug bolus was administered, and subsequent changes in the BIS index, concentration of volatile anesthetic, and arterial pressure were analyzed. Our primary outcome was change in BIS index, following drug administration. Adjusted 95% confidence intervals were compared to predetermined thresholds for clinical significance. Secondary sensitivity analyses examined the same outcomes, with available data separated according to differences in baseline volatile anesthetic concentrations, doses of the administered medications, and length of time window.

RESULTS::

The study cohort was comprised of data from 20,170 distinct cases, 54.7% of patients were men, with a median age of 55. In the primary analysis, ketamine at a median dose of 20 mg was associated with a median (confidence limits) increase in BIS index of 3.8 (2.5–5.0). Midazolam (median dose 2 mg) was associated with a median decrease in BIS index of 3.0 (1.5–4.5). Neither of these drug administrations occurred during time periods associated with changes in volatile anesthetic concentration. Analysis for dexmedetomidine was confounded by concomitant decreases in volatile anesthetic concentration. No other medication analyzed, including propofol and common opioids, was associated with a significant change in BIS index. Secondary analyses revealed that similar BIS index changes occurred when midazolam and ketamine were administered at different volatile anesthetic concentrations and different doses, and these changes persisted 11 to 20 minutes postadministration.

CONCLUSIONS::

Modest, but persistent changes in BIS index occurred following doses of ketamine (increase) and midazolam (decrease) during periods of stable volatile anesthetic administration.

01 Mar 2024·European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy

Article

Author: Wang, Ling ; Hu, Wei ; Dallmann, André ; Olkkola, Klaus T ; Ni, Liang ; Zheng, Liang ; Zhang, Qian ; Zhang, Wei ; Zhao, Yingjie

The concomitant administration of ritonavir and oxycodone may significantly increase the plasma concentrations of oxycodone. This study was aimed to simulate DDI between ritonavir and oxycodone, a widely used opioid, and to formulate dosing protocols for oxycodone by using physiologically based pharmacokinetic (PBPK) modeling. We developed a ritonavir PBPK model incorporating induction and competitive and time-dependent inhibition of CYP3A4 and competitive inhibition of CYP2D6. The ritonavir model was evaluated with observed clinical pharmacokinetic data and validated for its CYP3A4 inhibition potency. We then used the model to simulate drug interactions between oxycodone and ritonavir under various dosing scenarios. The developed model captured the pharmacokinetic characteristics of ritonavir from clinical studies. The model also accurately predicts exposure changes of midazolam, triazolam, and oxycodone in the presence of ritonavir. According to model simulations, the steady-state maximum, minimum and average concentrations of oxycodone increased by up to 166% after co-administration with ritonavir, and the total exposure increased by approximately 120%. To achieve similar steady-state concentrations, halving the dose with an unchanged dosing interval or doubling the dosing interval with an unaltered single dose should be practical for oxycodone, whether formulated in uncoated or controlled-release tablets during long-term co-medication with ritonavir. The results revealed exposure-related risks of oxycodone-ritonavir interactions that have not been studied clinically and emphasized PBPK as a workable method to direct judicious dosage.

News (Medical) associated with Midazolam

26 Jun 2024

·www.biospace.com

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine intravenous (IV) Crossject’s bioequivalence study, recently published in Neurology and Therapy, remarkably consistent with RAMPART’s findings and authors’ views Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART (Rapid Anticonvulsant Medication Prior to ARrival Trial) study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics. Status epilepticus is defined as a seizure lasting more than 5 minutes. RAMPART unequivocally raised IM midazolam to the status of standard-of-care in the pre-hospital emergency management of status epilepticus by demonstrating its non-inferiority vs. IV lorazepam, as its primary endpoint. Moreover, IM midazolam demonstrated statistically significant superiority (p value<0.001) on the percentage of patients arriving in hospital seizure-free, which was 10% higher when using IM midazolam (329 out of 448 patients or 73.4% vs. 63.4% in the IV lorazepam 445-patient arm). These results underscored the importance of the speed of IM administration of midazolam, as an easy to store and pre-prepared medication for use by paramedics, features that were likely critical in driving efficacy in controlling seizures by the time of arrival in emergency departments. RAMPART was one of the largest studies every conducted in emergency settings, involving 4,314 paramedics, 33 EMS (Emergency Medical Services) units and 79 hospital ER (Emergency Room) departments across the U.S. It was supported by the National Institute of Health (NIH) and by the Biomedical Advanced Research and Development Authority (BARDA). The RAMPART study publication can be found here. Crossject’s study, recently published in the peer-reviewed journal Neurology and Therapy, positively echoed the benefits implied from RAMPART and is remarkably consistent with certain hints put forward by the authors in the RAMPART study. In Crossject’s study, ZEPIZURE® was equivalent to the IM injection from a syringe equipped with a 30mm needle (Dormicum®), and results also suggested a 2-fold lower variability as compared to that usually observed for routes of administration such as intranasal. With some vision and based on their experience then, RAMPART authors had highlighted a number of issues regarding intranasal solutions in epileptic seizures in general, and their prediction of the likely dominance of the IM route for the future. Today, no intranasal solution is approved for the management of status epilepticus. According to RAMPART’s authors, the upfront minutes were critical factors in driving the 10% superiority of IM midazolam, administered through traditional manual vial-form injectable, in positive clinical outcome by ER arrival. ZEPIZURE®, as an ultra-rapid two-step injection, strongly resonates in this practical interventional reality and is likely to further improve the speed of action by healthcare professionals and reliability in injecting a full dose of midazolam. Furthermore, in Crossject’s study, ZEPIZURE® enhanced the midazolam absorption during the very first few minutes post-injection, possibly resulting from the needle-free 50 milliseconds injection compared to manual IM and suggesting that seizure treatment may be efficient even sooner. Patrick Alexandre, CEO of Crossject added: “Beyond the 505(b)(2) regulatory and market gate for ZEPIZURE® into the arsenal available to healthcare professionals in status epilepticus episodes, as potentially the most rapid-to-use and lowest variability tool for the delivery of a complete midazolam dose pre-hospital, our product presents additional upside. ZEPIZURE®’s rapid and easy two-step application should potentially require limited training compared to traditional injectables, and its consistency in administering an effective dose would confer a key advantage. ZEPIZURE® is therefore poised to provide all patients, and their relatives or caregivers, with the professional standard-of-pre-hospital-care solution anytime and anywhere. Our team in Europe and the U.S. is now executing our development strategy to materialize these broad prospects, aiming to position ZEPIZURE® from a productivity contribution to healthcare professionals toward a high impact solution for all patients and families at risk of a broad range of epilepsy seizures.” About Crossject Crossject SA (Euronext: ALCJ; ) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. Crossject is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency medicines via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * Contract no: 75A50122C00031 with the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Research and Development Authority For further information, please contact: Investors Natasha Drapeau Cohesion Bureau +41 76 823 75 27 natasha.drapeau@cohesionbureau.com Media Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com 1Silbergleit et al. New England Journal of Medicine, February 2012. Clinicaltrials.gov NCT05026567 Attachment PR RAMDORM 25 June 2024_v9

Clinical ResultClinical Study

24 Jun 2024

·www.globenewswire.com

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial. AKYNZEO injection (Ready-to-Use) is a new method of administration and contains the same formulation as the prior AKYNZEO Injection (To-be-Diluted). The features of the new ready-to-use presentation of AKYNZEO injection include: No reconstitution or dilution required; infuse directly from the vial using a built-in hanging strapNo refrigeration required at any point during distribution, storage, or preparationAccessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care AKYNZEO injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. It can be administered simultaneously with intravenous dexamethasone sodium phosphate. Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new AKYNZEO Ready-to-Use vial, building on our legacy of innovation.” Ordering information Clinicians wishing to order the new vial should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]). About AKYNZEO® AKYNZEO is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. INDICATION AKYNZEO (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs. Adverse Reactions Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, asthenia, dyspepsia, fatigue, constipation and erythema. The safety profile of AKYNZEO injection was generally similar to AKYNZEO capsules. Drug Interactions Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO. A more than two- fold increase in the systemic exposure of dexamethasone was observed 4 days after a single infusion of fosnetupitant.Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO. Use in Specific Populations Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.Advise women of potential risk to fetus; limited data are available; may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

Drug ApprovalClinical Result

06 Jun 2024

·www.biospace.com

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Topline Readout Expected in Q4 2024 NASHVILLE, Tenn.--(BUSINESS WIRE)-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast‑dissolving Zydis® delivery technology to rapidly dissolve the tablet for absorption across the sublingual mucosa. The MELT-300 Phase 3 clinical trial is a randomized, double-blind, three-arm study comparing – at a 4:1:1 ratio – MELT-300, sublingual midazolam, and sublingual placebo for procedural sedation in 528 patients undergoing cataract surgery at 14 participating clinical sites. The topline readout is expected in the fourth quarter of 2024. Melt previously announced the results from its MELT-300 Phase 2 clinical trial in patients undergoing cataract surgery. The Phase 2 clinical trial compared MELT-300 against (i) sublingual placebo alone, (ii) sublingual midazolam, and (iii) sublingual ketamine in over 300 patients. MELT-300 was statistically superior for procedural sedation compared to all individual comparator arms: (i) sublingual placebo (P <0.0001), (ii) sublingual midazolam (P=0.0129) and (iii) sublingual ketamine (P=0.0096). In commenting on the announcement, Dr. Larry Dillaha, Chief Executive Officer of Melt, said, “We are very excited to announce the first dosing in our pivotal Phase 3 program. Over the past 20 years, a lack of innovation in outpatient procedural sedation has created a significant unmet need, with IV‑administered medications being a procedural mainstay and contributing to an increase in opioid usage. We believe that MELT-300 could revolutionize procedural sedation while enhancing the patient’s experience in all sites of care by offering greater comfort without a needle stick and by reducing exposure to opioids.” Dr. Dillaha added, “While we are initially targeting sedation during cataract surgery for MELT-300, estimated to be over 5 million annual procedures in the U.S. in the coming years, we believe with further development and label expansion, MELT-300 could be utilized in over 100 million annual procedures in areas such as dermatology, plastics, dental, gastrointestinal, and emergency rooms.” About Melt Pharmaceuticals Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing proprietary non-opioid, non-IV, sedation, and analgesia therapeutics for human medical procedures in the hospital, outpatient, and in-office settings. Melt intends to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for its proprietary, patented small-molecule product candidates, where possible. Melt’s core intellectual property is the subject of multiple granted patents in North America, Europe, Asia, and the Middle East. Melt Pharmaceuticals, Inc. is a former subsidiary of Harrow, Inc. (Nasdaq: HROW) and was carved out as a separately managed business in 2019. To learn more about Melt, please visit their website, .

Phase 3Phase 2Clinical Result

100 Deals associated with Midazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D00550	-	N05CD08	DB00683

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Epilepsy	US	UCB, Inc.	17 May 2019
Status Epilepticus	JP	Alfresa Pharma Corp.	26 Sep 2014
Sedation	CN	Jiangsu Nhwa Pharmaceutical Co., Ltd.	01 Jan 1998
Anesthesia	JP	Maruishi Pharmaceutical Co., Ltd.	29 Mar 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute repetitive seizure	Phase 3	US	UCB Biopharma SRL	01 May 2014
Hepatitis C, Chronic	Phase 1	CN	Sunshine Lake Pharma Co. Ltd.	02 Nov 2022
COVID-19	Phase 1	US	Pfizer Inc.	17 Oct 2022
COVID-19	Phase 1	BE	Pfizer Inc.	17 Oct 2022
Advanced Malignant Solid Neoplasm	Phase 1	US	AstraZeneca PLC	15 Oct 2021
Obesity	Phase 1	US	Pfizer Inc.	15 Dec 2020
Cardiovascular Diseases	Phase 1	GB	AstraZeneca PLC	30 Jul 2020
Autism Spectrum Disorder	Phase 1	GB	Hoffmann-La Roche, Inc.	15 Jul 2020
Autistic Disorder	Phase 1	GB	Hoffmann-La Roche, Inc.	15 Jul 2020
Neurocognitive Disorders	Phase 1	GB	Hoffmann-La Roche, Inc.	15 Jul 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04051827 (CTgov)	Phase 1	Advanced Lung Non-Small Cell Carcinoma	26	Midazolam (Part A: Midazolam Alone)	simtpknask(qojggekoii) = tuhmonwuzb edcxjywbtp (inljkwycmi, crvgmvdova - kauyzrnhsl) View more	-	12 Apr 2024
				Midazolam+Mobocertinib (Part A: Midazolam + Mobocertinib)	simtpknask(qojggekoii) = tjohokmoka edcxjywbtp (inljkwycmi, projpuozwa - yslagctzfe) View more
NCT03815344 (CTgov)	Phase 4	-	74	Standard-vaginal misoprostol (Standard)	xzfidzrbez(xdjulxuzbr) = vrqauljavn lrneieehrx (uptbzjwhqa, ueadudtgtg - sbsvbthlsv) View more	-	09 Jan 2024
				Standard-vaginal misoprostol+Standard (Standard-Vaginal Misoprostol)	xzfidzrbez(xdjulxuzbr) = lrftcfylpr lrneieehrx (uptbzjwhqa, zzmkgsodwr - qompsiryof) View more
NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Meperidine+Hydroxyzine+Midazolam (Midazolam, Hydroxyzine, Meperidine)	waisdposvr(wzcmhftwsh) = vzgpkiucbj uwmpkdowec (ohrncvfrsw, cnmepvqcsy - qdynhemimw) View more	-	05 Dec 2023
				Hydroxyzine+Midazolam (Midazolam, Hydroxyzine)	waisdposvr(wzcmhftwsh) = qdqcqxkfwr uwmpkdowec (ohrncvfrsw, xzhgreathh - uqtjjnopmw) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	opatswmgxp(yotdgvqlvs) = bmbqwaockd xqqckvlqhu (hehcslczai, ubftwzyyda - cacxouutyj) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	opatswmgxp(yotdgvqlvs) = oyzltplnbn xqqckvlqhu (hehcslczai, sbxelojgbw - zpwrgbuwko) View more
NCT05032950 (CTgov)	Phase 1	COVID-19	12	Midazolam (Midazolam 2 mg)	rsbaucxzcu(llepplkbrg) = pjvbiwxpvn tyqjenpbgw (esrhtokxhx, lwoxzqtyvs - ogsfgspysr) View more	-	04 Oct 2023
				PF-07321332+Midazolam+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg + Midazolam 2 mg)	rsbaucxzcu(llepplkbrg) = dtknvddgxn tyqjenpbgw (esrhtokxhx, gmnbcxpydi - pfstxwlbxl) View more
NCT03420742 (CTgov)	Phase 1	Neoplasms \| ALK Positive Solid Tumors	24	Midazolam (Part A, Cycle 1 Day 1: Midazolam Alone)	jdvwcjytwd(iswsokwkrh) = aeffnzeykm obyhjvzekd (ubsvmuyjsj, zkpztcintj - pcsmuqtsms) View more	-	27 Jan 2023
				Midazolam+Brigatinib (Part A, Cycle 1 Day 21: Midazolam + Brigatinib)	jdvwcjytwd(iswsokwkrh) = avwwvzrqwf obyhjvzekd (ubsvmuyjsj, rjronoydch - wtpceqzavy) View more
Pubmed	Phase 1	ALK Positive Solid Tumors	-	Brigatinib	tcqdkafjeu(tctvzfglya) = keldnkqtcu xvrlthiotv (jjyijsmicb ) View more	-	29 Dec 2022
ChiCTR1800015038 (Pubmed)	Not Applicable	Sedation	156	3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam	xmsibvymtz(cyixxvyrio) = sknnidstyy xjlwvlycjt (vgxmjbimia ) View more	-	23 Nov 2022
				2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam	xmsibvymtz(cyixxvyrio) = hidzeswufi xjlwvlycjt (vgxmjbimia ) View more
NCT03813121 (CTgov)	Phase 1/2	Tobacco Use Disorder	10	placebo intravenous infusion (Placebo Intravenous Infusion)	notrlcqxcm(eocpotrfwg) = iyflujjnye sqodhycxfr (htxoeholyq, fnfnoougxu - ncecdohixq) View more	-	02 Jun 2022
				ketamine intravenous infusion (Ketamine Intravenous Infusion)	notrlcqxcm(eocpotrfwg) = xzlsmeoyev sqodhycxfr (htxoeholyq, hslkqxmdmd - mnhamcbtjx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis